To date, little evidence is available regarding novel BTK-inhibitors, such as acalabrutinib, and their effect on autoimmune complications in CLL, but results of a phase II study evaluating acalabrutinib monotherapy in 134 R/R CLL showed only one recurrence of AIHA among 11 patients with history of AIC [36]. Here, BTK is linked to autoimmune hemolytic anemia.